FDA Approves Shingrix for Shingles

The FDA approved GlaxoSmithKline’s Shingrix vaccine for treatment of shingles in adults 50 and over.

An FDA advisory committee endorsed Shingrix in September.

Shingrix is a non-live, recombinant subunit vaccine for shingles and its complications, such as postherpetic neuralgia.

Merck’s Zostavax is the only other FDA-approved shingles vaccine.